Table 1.

Protein expression levels and MVD in xenografts recovered from mice treated with AS Bcl-2 ODN, irradiation, or in combination after s.c. implantation of human PC-3-Bcl-2 prostate cancer cells

Treatment groupProtein expression*
MVD (per ×200 field)
Bcl-2VEGF
Mock no XRT10010078 ± 22
Mock + XRT1087364 ± 19
CTL no XRT1189656 ± 24
CTL + XRT1525337 ± 2.5
AS Bcl-2 ODN no XRT527516 ± 19
AS Bcl-2 ODN + XRT482915 ± 2.4
  • * The intensity of the cytoplasmic immunostaining was measured by an image analyzer in three different areas of each sample to yield an average measurement. Results for each group were expressed as the average of the five areas of highest intensity identified within a single ×200 field (26).

  • Microvessel density was evaluated by CD31 immunostaining. Values are expressed as the average of the five areas of highest density identified within a single ×200 field ± SD.

  • P < 0.05 versus mock (Mann-Whitney statistical comparison).